Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
No off-season for dupilumab. New data from a post hoc analysis of the BOREAS and NOTUS trials show that dupilumab consistently reduced moderate-to-severe COPD exacerbations across all four seasons compared to placebo. The biggest reductions were seen in summer and spring, but even winter — peak respiratory infection season — showed a meaningful 26% drop in flare-ups.
No off-season for dupilumab
New data presented at the European Respiratory Society International Congress confirm that dupilumab (Dupixent) reduces moderate-to-severe COPD exacerbations year-round — not just during certain times of year. The findings come from a post hoc analysis of the phase 3 BOREAS and NOTUS trials, which enrolled adults aged 40–85 with COPD, type 2 inflammation, and moderate-to-severe airflow limitation on triple inhaled therapy.
Researchers found that patients on dupilumab had fewer exacerbations in every season compared to placebo, with the largest reductions in summer and spring (both –33%) and meaningful reductions in fall (–27%) and winter (–26%). Dupilumab-treated patients also required fewer courses of both systemic corticosteroids and antibiotics across all seasons.
By the Numbers:
Why it matters: Since viral and bacterial infections — the main drivers of COPD exacerbations — peak in winter, there was concern that a biologic targeting type 2 inflammation might be less effective during high-risk seasons. These results put that concern to rest, giving clinicians confidence that dupilumab delivers consistent protection regardless of when patients are enrolled or treated.
